Etoposide: a pharmacokinetic profile including an assessment of bioavailability.
Med Oncol Tumor Pharmacother
; 3(2): 95-9, 1986.
Article
en En
| MEDLINE
| ID: mdl-3018396
ABSTRACT
The pharmacokinetics of intravenous etoposide (50-150 mg m-2) have been studied in 17 patients. Bioavailability studies on either the capsule or intravenous (i.v.) formulation were performed in 13 patients, 7 of whom received both oral formulations given in the dose range 50-250 mg m-2. After i.v. administration the mean +/- SD half-lives were t1/2 alpha 0.62 +/- 1.01 h and t1/2 beta 6.04 +/- 2.5 h. The bioavailability of etoposide was extremely variable for the capsule it was 38 +/- 14% (range 10-55) and for the i.v. formulation it was 53 +/- 25% (range 31-88). The i.v. formulation was not significantly better than the capsule. The results confirm the low and variable bioavailability of oral etoposide.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Podofilotoxina
/
Etopósido
/
Neoplasias
Límite:
Female
/
Humans
/
Male
Idioma:
En
Año:
1986
Tipo del documento:
Article